Advertisement Wyeth and Takeda introduce new formulation of arthritis drug - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Wyeth and Takeda introduce new formulation of arthritis drug

Wyeth and Takeda Pharmaceutical Company have launched Enbrel 25mg Syringe 0.5mL for SC Injection, a new formulation of Enbrel for the treatment of rheumatoid arthritis, that is being co-promoted by the two companies.

Enbrel 25mg Syringe 0.5mL for SC Injection is a new formulation of the existing Enbrel 25mg for SC Injection, with the drug pre-filled into the syringe.

According to the company, the launch of Enbrel 25mg Syringe 0.5mL for SC Injection offers easier preparations for administration for patients who self-inject Enbrel as well as medical professionals, leading to a decrease in the burden for them.